<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anagrelide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anagrelide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Anagrelide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8593" href="/d/html/8593.html" rel="external">see "Anagrelide: Drug information"</a> and <a class="drug drug_patient" data-topicid="10932" href="/d/html/10932.html" rel="external">see "Anagrelide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F135406"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Agrylin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865934"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Agry-Gen;</li>
<li>Agrylin;</li>
<li>PMS-Anagrelide;</li>
<li>SANDOZ Anagrelide [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F998261"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiplatelet Agent</span>;</li>
<li>
<span class="list-set-name">Phosphodiesterase Enzyme Inhibitor</span>;</li>
<li>
<span class="list-set-name">Phosphodiestrerase-3 Enzyme Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F135418"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c7a435d-961f-41cc-9695-65c5bcc38019">Essential thrombocythemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Essential thrombocythemia: </b>Very limited data available; several small case series: Children ≥6 years and Adolescents: Oral: Initial: 0.5 mg 2-3 times daily; increase at weekly intervals in 0.5 mg increments until platelet count begins to decrease; usual reported maintenance dose range: 1-2.5 mg/day; maximum daily dose: 10 mg/<b>day</b> (per manufacturer) although the maximum reported dose for essential thrombocythemia: 4 mg/<b>day</b>; once platelet count normalizes, further adjust dose to lowest effective dose; in some cases, discontinuation of therapy has been accomplished (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7658287','lexi-content-ref-9787322','lexi-content-ref-16856926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7658287','lexi-content-ref-9787322','lexi-content-ref-16856926'])">Ref</a></span>); <b>Note:</b> Essential thrombocytopenia is also considered a type myeloproliferative disorder.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f48df7f0-ac55-4813-bc2d-77c8e61c1dfb">Secondary thrombocythemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary thrombocythemia (associated with myeloproliferative disorders):</b> Children &gt;6 years and Adolescents: Oral: Initial: 0.5 mg once daily; usual range: 0.5 mg 1-4 times daily; median maintenance daily dose: Patient age 7-11 years: 1.75 mg/day; patient age: 11-14 years: 2 mg; <b>Note:</b> Maintain initial dose for ≥1 week, then adjust to the lowest effective dose to reduce and maintain platelet count &lt;600,000/mm<sup>3</sup> ideally to the normal range; the dose must not be increased by &gt;0.5 mg per day in any 1 week; maximum single dose: 2.5 mg; maximum daily dose: 10 mg/<b>day</b></p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51064849"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;">Children and Adolescents: No adjustment required in renal insufficiency; monitor closely.</p></div>
<div class="block doa drugH1Div" id="F135409"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8593" href="/d/html/8593.html" rel="external">see "Anagrelide: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c7a435d-961f-41cc-9695-65c5bcc38019">Essential thrombocythemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Essential thrombocythemia (alternative agent):</b> Oral: Initial: 0.5 mg 4 times daily or 1 mg twice daily (most patients will experience adequate response at dose ranges of 1.5 to 3 mg per day).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dose titration:</i> Maintain initial dose for at least 1 week, then titrate to reduce and maintain platelet count &lt;600,000/mm<sup>3</sup> and ideally between 150,000/mm<sup>3</sup> and 400,000/mm<sup>3</sup>; the dose must not be increased by &gt;0.5 mg per day in any 1 week; maximum single dose: 2.5 mg; maximum daily dose: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i> Oral: 0.5 mg twice daily for 1 week, then adjust dose to maintain platelet counts at normal (≤450,000/mm<sup>3</sup>) or near normal (450,000/mm<sup>3</sup> to 600,000/mm<sup>3</sup>) levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23315161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23315161'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991628"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling; however, CrCl &lt;30 mL/minute had no significant effect on anagrelide pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26714677'])">Ref</a></span>)</p></div>
<div class="block doha drugH1Div" id="F50988914"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh score 7 to 9): Initial: 0.5 mg once daily; maintain for at least 1 week with careful monitoring of cardiovascular status; if tolerated, may increase dose; the dose must not be increased by &gt;0.5 mg per day in any 1 week.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh score ≥10): Avoid use.</p></div>
<div class="block adr drugH1Div" id="F135381"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency of adverse reactions is similar in adult and pediatric patients. Listed incidences are for adults unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (21%), palpitations (26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (16%), diarrhea (26%), nausea (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (15%), headache (44%), pain (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular<b>: </b>Angina pectoris (1% to 5%), cardiac arrhythmia (1% to 5%), chest pain (8%), heart failure (1% to 5%), hypertension (1% to 5%), orthostatic hypotension (1% to 5%), peripheral edema (9%), syncope (1% to 5%), tachycardia (8%), vasodilation (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (1% to 5%), ecchymoses (1% to 5%), pruritus (6%), skin rash (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (8%), constipation (1% to 5%), dyspepsia (5%), flatulence (10%), gastritis (1% to 5%), gastrointestinal hemorrhage (1% to 5%), vomiting (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (1% to 5%), hemorrhage (1% to 5%), thrombocytopenia (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Amnesia (1% to 5%), chills (1% to 5%), confusion (1% to 5%), depression (1% to 5%), drowsiness (1% to 5%), insomnia (1% to 5%), malaise (6%), migraine (1% to 5%), nervousness (1% to 5%), paresthesia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (1% to 5%), back pain (6%), myalgia (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia (1% to 5%), visual disturbance (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (6%), epistaxis (1% to &lt;5%), flu-like symptoms (1% to 5%), pneumonia (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (9%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Supraventricular tachycardia, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hypoesthesia</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular<b>: </b>Acute myocardial infarction, atrial fibrillation, cardiomegaly, cardiomyopathy, cerebrovascular accident, complete atrioventricular block, pericardial effusion, prolonged QT interval on ECG</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (pediatric patients)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps (pediatric patients)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pleural effusion, pulmonary fibrosis, pulmonary hypertension, pulmonary infiltrates</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cerebral infarction, Prinzmetal angina, torsades de pointes</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin photosensitivity (pediatric patients)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukocytosis (pediatric patients)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (including increased serum alanine aminotransferase [&gt;3 x ULN], increased serum aspartate aminotransferase [&gt;3 x ULN])</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pulmonary disease (including eosinophilic pneumonitis, hypersensitivity pneumonitis, interstitial pneumonitis)</p></div>
<div class="block coi drugH1Div" id="F135394"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the US manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to anagrelide or any component of the formulation; severe hepatic impairment; rare heredity condition of galactose intolerance, glucose-galactose malabsorption, or congenital lactase deficiency.</p></div>
<div class="block war drugH1Div" id="F135378"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding risk: The risk for major hemorrhagic events is increased when anagrelide is used concomitantly with aspirin; assess risks versus benefits if using anagrelide in combination with aspirin. Monitor for bleeding, particularly when used concurrently with other agents known to increase bleeding risk (eg, anticoagulants, nonsteroidal anti-inflammatory drugs, antiplatelet agents, other phosphodiesterase 3 [PDE3] inhibitors, selective serotonin reuptake inhibitors).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular adverse events: Ventricular tachycardia and torsades de pointes have been reported with anagrelide. As with other PDE3 inhibitors, anagrelide may cause vasodilation, tachycardia, palpitations and heart failure. PDE3 inhibitors are associated with decreased survival (compared to placebo) in patients with class III or IV heart failure. In a scientific statement from the American Heart Association, anagrelide has been determined to be an agent that may cause direct myocardial toxicity (magnitude: major) (AHA [Page 2016]). Dose-related increases in heart rate and mean QTc interval have been observed in a clinical trial. The maximum change in mean heart rate was ~8 beats per minute (bpm) at a dose of 0.5 mg and ~29 bpm with a 2.5 mg dose. The maximum mean change in QTc I (individual subject correlation) from placebo was 7 msec and 13 msec with doses of 0.5 and 2.5 mg, respectively. Do not use in patients with hypokalemia, congenital long QT syndrome, a known history of acquired QTc prolongation, or when using concomitant therapy that may prolong the QTc interval. Hypotension accompanied by dizziness may occur, particularly with higher doses. Consider periodic ECG monitoring in patients with heart failure, bradyarrhythmias, or electrolyte abnormalities. The benefits of anagrelide therapy should outweigh risks in patients with cardiovascular disease. Pretreatment cardiovascular evaluation (including ECG) and careful monitoring during treatment is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary hypertension: Pulmonary hypertension has been reported with anagrelide; evaluate for signs and symptoms of underlying cardiopulmonary disease prior to and during anagrelide therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Interstitial lung disease (including allergic alveolitis, eosinophilic pneumonia, and interstitial pneumonitis) has been associated with anagrelide. The onset is from 1 week to several years after anagrelide initiation, usually presenting with progressive dyspnea with lung infiltrations; symptoms usually improve after discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal abnormalities: Renal abnormalities (including hematuria and renal failure) have been observed with anagrelide.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Hepatic impairment increases anagrelide exposure and may increase the risk of QTc prolongation. Assess risks versus benefits of anagrelide treatment in patients with mild to moderate hepatic impairment; dosage reduction and careful cardiovascular monitoring are required for moderate impairment. Avoid use in patients with severe impairment. Monitor liver function prior to and during treatment.</p></div>
<div class="block foc drugH1Div" id="F135388"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Agrylin: 0.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg</p></div>
<div class="block geq drugH1Div" id="F135374"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F135396"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Agrylin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $9.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Anagrelide HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $11.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $24.07</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865935"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Agrylin: 0.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg</p></div>
<div class="block admp drugH1Div" id="F52612240"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">May be administered without regard to food.</p></div>
<div class="block adm drugH1Div" id="F5172803"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food.</p></div>
<div class="block sts drugH1Div" id="F5172800"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53565439"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of thrombocythemia secondary to myeloproliferative disorders to decrease elevated platelet count and the associated risk of thrombosis and ameliorate symptoms including thrombo-hemorrhagic events (FDA approved in ages &gt;6 years and adults)</p></div>
<div class="block mst drugH1Div" id="F6884123"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Anagrelide may be confused with anastrozole</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F135420"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F135383"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Anagrelide may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Anagrelide may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: Anagrelide may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilostazol: Anagrelide may enhance the adverse/toxic effect of Cilostazol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inducers (Moderate): May decrease serum concentrations of the active metabolite(s) of Anagrelide. CYP1A2 Inducers (Moderate) may decrease the serum concentration of Anagrelide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Moderate): May increase serum concentrations of the active metabolite(s) of Anagrelide. CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Anagrelide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Anagrelide. CYP1A2 Inhibitors (Strong) may increase the serum concentration of Anagrelide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoximone: May enhance the adverse/toxic effect of Anagrelide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Levoketoconazole.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Milrinone: Anagrelide may enhance the adverse/toxic effect of Milrinone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Anagrelide may enhance the hypotensive effect of Riociguat.  Management: Riociguat is contraindicated with nonselective phosphodiesterase (PDE) inhibitors and PDE type 5 inhibitors. Other types of PDE inhibitors are not contraindicated, but caution is advised and patients should be monitored for hypotension.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F135397"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Data regarding use of anagrelide during pregnancy is limited (Alkindi 2005; Birgegård 2018; Cornet 2017; Doubek 2004; Sobas 2009; Wright 2001).</p>
<p style="text-indent:0em;margin-top:2em;">Thrombocythemia is associated with an increased risk for adverse pregnancy outcomes including miscarriage, stillbirth, and preeclampsia. When treatment for essential thrombocythemia is needed during pregnancy, other agents are currently preferred (Tefferi 2018).</p></div>
<div class="block mopp drugH1Div" id="F53565438"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Platelet count (every 2 days during the first week of treatment and at least weekly until the maintenance dose is reached; continue to monitor after cessation of treatment); CBC with differential (monitor closely during first 2 weeks of treatment), liver function (ALT and AST; baseline and during treatment), BUN, and serum creatinine (monitor closely during first weeks of treatment); serum electrolytes; blood pressure; heart rate; cardiovascular exam including ECG (pretreatment; monitor during therapy), signs/symptoms of interstitial lung disease. Monitor for thrombosis or bleeding.</p></div>
<div class="block pha drugH1Div" id="F135377"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Anagrelide appears to inhibit cyclic nucleotide phosphodiesterase and the release of arachidonic acid from phospholipase, possibly by inhibiting phospholipase A<sub>2</sub>. Anagrelide also causes a dose-related reduction in platelet production, which results from decreased megakaryocyte hypermaturation (disrupts the postmitotic phase of maturation).</p></div>
<div class="block phk drugH1Div" id="F135393"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Initial: Within 7 to 14 days; complete response (platelets ≤600,000/mm<sup>3</sup>): 4 to 12 weeks</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Platelet rebound: Variable; upon discontinuation, platelet count begins to rise within 4 days and returns to baseline in 1 to 2 weeks (may rebound above baseline)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; primarily via CYP1A2 to two major metabolites, 3-hydroxy anagrelide (active) and RL603 (inactive)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Anagrelide: ~1.5 hours, similar data reported in pediatric patients 7 to 14 years of age; 3-hydroxy anagrelide: ~2.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: ~1 hour (in fasted state), similar data reported in pediatric patients 7 to 14 years of age</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;1% as unchanged drug; ~3% as 3-hydroxy anagrelide [active metabolite]; 16% to 20% as RL603 [inactive metabolite])</p></div>
<div class="block phksp drugH1Div" id="F51220436"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC increased 8-fold in patients with moderate hepatic function impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: AUC and C<sub>max</sub> of anagrelide were 61% and 36% higher, respectively, in patients ages 65 to 75 years compared to patients ages 22 to 50 years, but the AUC and C<sub>max</sub> of the active metabolite, 3-hydroxy anagrelide, were 37% and 42% lower, respectively, in the older adult population.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: In pediatric patients 7 to 14 years of age; data have shown a decreased maximum serum concentration (48%) and AUC (55%) compared to adults when normalized to dose and bodyweight.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F135398"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Agrylin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Agrelid | Inaro</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Anagrelid bluefish | Anagrelid ratiopharm | Thromboreductin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Agrylin | Anagrelide apotex | Anagrelide scp</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Anagrelid sandoz | Atremia | Xagrid</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Thromboreductin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Agrylin | Monboc</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Thromboreductin | Xagrid</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Zalenia</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Anagrelide | Gralidex</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alegriten | Anagrelid Leram | Anagrelid mylan | Anagrelid sandoz | Anagrelid stada | Anagrelide glenmark | Anagrelide teva | Anagrelide vipharm | Thromboreductin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Anagrelid abz | Anagrelid al | Anagrelid aop | Anagrelid beta | Anagrelid bluefish | Anagrelid glenmark | Anagrelid heumann | Anagrelid hexal | Anagrelid mylan | Anagrelid puren | Anagrelid ratiopharm | Anagrelid ribosepharm | Anagrelid zentiva | Xagrid | Xeralid</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Anagrelide mylan | Xagrid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Thrombonorm</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Anagrelida accordpharma | Anagrelida aristo | Anagrelida aurovitas | Anagrelida glenmark | Anagrelida ratiopharm | Anagrelida stada | Anagrelida teva | Xagrid</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Anagrelid avansor | Anagrelid Orion | Anagrelide mylan | Anagrelide ratiopharm | Anagrelide stada | Xagrid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Agrelin | Anagrelide arrow | Anagrelide biogaran | Anagrelide EG | Anagrelide mylan | Anagrelide Sandoz | Anagrelide teva | Anagrelide zentiva | Xagrid</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Anagrelide | Anagrelide dr. reddy's | Anagrelide glenmark | Anagrelide milpharm | Anagrelide zentiva | Xagrid</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Agrylin | Anagrelide mylan | Anagrelide teva</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Agrylin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Anagrelid Alpha Medical | Thromboreductin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Anagrelid pharmacenter | Anagrelide Sandoz | Anagrelide stada | Anagrelide vipharm</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Thromboreductin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Agrylin | Xagrid</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Agrylin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Anagrelide accord | Anagrelide Aurobindo | Anagrelide mylan | Anagrelide Sandoz | Anagrelide teva | Xagrid</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Agrylin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Agrylin | Anagre | Anarid | Hagrygen</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Anagrelide biogaran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Agrylin | Anagrelide mylan | Gralidon | Thromboreductin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Atremia | Xagrid</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Anagrelide mylan | Anagrelide teva | Gralidon</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Agrylin | Thromboreductin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Anagrelide accord | Anagrelide glenmark | Anagrelide Sandoz | Anagrelide teva | Xagrid</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Agrelin | Anagrelide aop | Anagrelide bluefish | Anagrelide Sandoz | Xagrid</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Agrylin | Anagrelide</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Anagrelide | Thromboreductin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Thromboreductin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Agrylin | Anagrelide accord | Anagrelide Bioton | Anagrelide bluefish | Anagrelide glenmark | Anagrelide mylan | Anagrelide Ranbaxy | Anagrelide Sandoz | Anagrelide stada | Anagrelide vipharm | Anagrelide zentiva | Atremia | Grenalvon | Thromboreductin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Agrylin | Anagrelide | Anagrelide HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Agrylin | Anagrelida accord | Anagrelida bluefish | Anagrelida generis | Anagrelide | Xagrid</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Anagrelida accord | Anagrelida Aurobindo | Anagrelida dr reddys | Anagrelida glenmark | Anagrelida mylan | Anagrelida Sandoz | Anagrelida terapia | Anagrelida teva | Anagrelida zentiva | Grenalvon | Xagrid</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Agrylin | Anagrelide | Thromboreductin | Tromboreductin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Agrylin | Pms anagrelide</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Anagrelid accordpharma | Anagrelid avansor | Anagrelid Orion | Anagrelide aop | Anagrelide bluefish | Anagrelide glenmark | Anagrelide mylan | Anagrelide Sandoz | Anagrelide stada | Xagrid</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Agrylin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Anagrelid sandoz | Anagrelid stada | Anagrelid teva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Anagrelid aop | Anagrelid stada | Anagrelide glenmark | Anagrelide mylan | Anagrelide teva | Anagrelide vipharm | Anamed | Thromboreductin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Agrylin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Xagrid</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Greline | Xagrilyn</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Agrylin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Anagrelid vista</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Agrylin | Thromboreductin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Agrylin.1">
<a name="Agrylin.1"></a>Agrylin (anagrelide) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Agrylin.2">
<a name="Agrylin.2"></a>Agrylin (anagrelide) [product monograph]. Toronto, Ontario, Canada: Takeda Canada Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15959777">
<a name="15959777"></a>Alkindi S, Dennison D, Pathare A. Successful outcome with anagrelide in pregnancy. <i>Ann Hematol</i>. 2005;84(11):758-759.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/15959777/pubmed" id="15959777" target="_blank">15959777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29079600">
<a name="29079600"></a>Birgegård G, Besses C, Griesshammer M, et al. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. <i>Haematologica</i>. 2018;103(1):51-60. doi: 10.3324/haematol.2017.174672.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/29079600/pubmed" id="29079600" target="_blank">29079600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7658287">
<a name="7658287"></a>Chintagumpala MM, Kennedy LL, Steuber CP. Treatment of essential thrombocythemia with anagrelide. <i>J Pediatr</i>. 1995;127:495-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/7658287/pubmed" id="7658287" target="_blank">7658287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28866127">
<a name="28866127"></a>Cornet N, Vialard F, Mir O, Berveiller P. Is anagrelide safe during pregnancy? <i>J Gynecol Obstet Hum Reprod</i>. 2017;46(9):697-699. doi: 10.1016/j.jogoh.2017.08.005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/28866127/pubmed" id="28866127" target="_blank">28866127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15278298">
<a name="15278298"></a>Doubek M, Brychtova Y, Doubek R, et al, “Anagrelide Therapy in Pregnancy: Report of a Case of Essential Thrombocythemia,” <i>Ann Hematol</i>, 2004, 83(11):726-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/15278298/pubmed" id="15278298" target="_blank">15278298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22262773">
<a name="22262773"></a>Giona F, Teofili L, Moleti ML, et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. <i>Blood</i>. 2012;119(10): 2219-2227.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/22262773/pubmed" id="22262773" target="_blank">22262773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23315161">
<a name="23315161"></a>Gisslinger H, Gotic M, Holowiecki J, et al; ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. <i>Blood.</i> 2013;121(10):1720-1728. doi: 10.1182/blood-2012-07-443770.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/23315161/pubmed" id="23315161" target="_blank">23315161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16000354">
<a name="16000354"></a>Harrison CN, Campbell PJ, Buck G, et al, “Hydroxyurea Compared With Anagrelide in High-Risk Essential Thrombocythemia,” <i>N Engl J Med</i>, 2005, 353(1):33-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/16000354/pubmed" id="16000354" target="_blank">16000354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16856926">
<a name="16856926"></a>Lackner H, Urban C, Benesch M, et al. Long-term use of anagrelide in the treatment of children with essential thrombocythemia. <i>Eur J Haematol</i>. 2006;77:358-359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/16856926/pubmed" id="16856926" target="_blank">16856926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9787322">
<a name="9787322"></a>Lackner H, Urban C, Beham-Schmid C, et al. Treatment of children with anagrelide for thrombocythemia. <i>J Pediatr Hematol/Oncol</i>. 1998;20(5): 469-473.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/9787322/pubmed" id="9787322" target="_blank">9787322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15531452">
<a name="15531452"></a>Mazzucconi MG, Redi R, Bernasconi S, et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. <i>Hematologica</i>. 2004;89:1306-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/15531452/pubmed" id="15531452" target="_blank">15531452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19887779">
<a name="19887779"></a>Sobas MA, Pérez Encinas MM, Rabuñal Martinez MJ, Quinteiro García C, Bello López JL. Anagrelide treatment in early pregnancy in a patient with JAK2V617F-positive essential thrombocythemia: case report and literature review. <i>Acta Haematol</i>. 2009;122(4):221-222. doi: 10.1159/000253030.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/19887779/pubmed" id="19887779" target="_blank">19887779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17882280">
<a name="17882280"></a>Tefferi A and Vardiman JW, “Classification and Diagnosis of Myeloproliferative Neoplasms: The 2008 World Health Organization Criteria and Point-of-Care Diagnostic Algorithms,” <i>Leukemia</i>, 2008, 22(1):14-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/17882280/pubmed" id="17882280" target="_blank">17882280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29321520">
<a name="29321520"></a>Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. <i>Blood Cancer J</i>. 2018;8(1):2. doi: 10.1038/s41408-017-0041-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/29321520/pubmed" id="29321520" target="_blank">29321520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26242182">
<a name="26242182"></a>Vannucchi AM, Barbui T, Cervantes F, et al; ESMO Guidelines Committee. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2015;26(suppl 5):v85-v99. doi: 10.1093/annonc/mdv203.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/26242182/pubmed" id="26242182" target="_blank">26242182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11350483">
<a name="11350483"></a>Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. <i>Eur J Haematol</i>. 2001;66(3):152-159.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anagrelide-pediatric-drug-information/abstract-text/11350483/pubmed" id="11350483" target="_blank">11350483</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 91068 Version 189.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
